Jazz Pharmaceuticals agrees $820 million Actio Biosciences acquisition to add precision epilepsy therapy ABS-1230

The acquisition would add a clinical-stage KCNT1 inhibitor for a rare genetic epilepsy with no FDA-approved treatments, while Actio’s remaining programmes will be transferred into a separate privately held company.

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront, with Actio shareholders eligible for up to a further $500 million in regulatory and sales milestones, giving the transaction a potential value of up to $1.32 billion.

The acquisition centres on ABS-1230, a clinical-stage precision therapy targeting the KCNT1 ion channel in patients with KCNT1-related epilepsy, and would expand Jazz’s established epilepsy portfolio into a genetically defined disease population.

Field	Content
Alert Type	Deal
Companies	Jazz Pharmaceuticals; Actio Biosciences
Deal Type	Acquisition
Asset or Company	Actio Biosciences, principally ABS-1230
Therapy Area(s)	Neurology; Epilepsy; Rare genetic diseases
Technology or Modality	Oral small-molecule KCNT1 ion-channel inhibitor
Deal Value	$820 million upfront, plus up to $500 million in contingent regulatory approval and sales milestone payments. The maximum potential consideration is approximately $1.32 billion, but the additional $500 million is not guaranteed.
Development Stage	Phase Ib/IIa
Geography	Global
What Happened	On 10 August 2026, Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent regulatory and sales milestones. The principal programme included in the acquisition is ABS-1230, an oral small-molecule KCNT1 inhibitor currently being evaluated in the Phase Ib/IIa KYRON study for KCNT1-related epilepsy. Before closing, certain Actio employees and assets unrelated to ABS-1230 will be transferred into a new privately held company, in which Jazz will receive a minority interest and certain rights. The acquisition remains subject to customary closing conditions.
Why It Matters	ABS-1230 gives Jazz a clinical-stage precision medicine programme targeting the ion-channel dysfunction underlying KCNT1-related epilepsy, a rare developmental and epileptic encephalopathy with no FDA-approved treatment specifically for the condition. The programme complements Jazz’s existing epilepsy franchise while giving the company exposure to a genetically targeted therapeutic approach, although its clinical value remains to be established in ongoing trials.
Supporting Context	KCNT1-related epilepsy is a rare genetic disorder associated with severe, frequently treatment-resistant seizures that often begin in infancy. ABS-1230 is designed to selectively inhibit overactive KCNT1 potassium channels caused by disease-associated variants and has entered the FDA’s Rare Disease Evidence Principles process.
Strategic Rationale	Jazz gains a clinical-stage precision epilepsy programme that complements its existing neuroscience portfolio without acquiring all of Actio’s pipeline. Actio’s remaining programmes, including the TRPV4 inhibitor ABS-0871 for Charcot-Marie-Tooth disease type 2C, are expected to continue within the new spinout company.
Potential Impact	If ABS-1230 demonstrates sufficient safety and efficacy and secures regulatory approval, Jazz could add a genetically targeted therapy for a small epilepsy population with substantial unmet need. The programme’s eventual clinical and commercial contribution remains dependent on successful development and regulatory review.
Key Takeaway	The acquisition gives Jazz a clinical-stage precision therapy targeting the underlying channel dysfunction in KCNT1-related epilepsy, extending its epilepsy portfolio into a genetically defined rare disease.
What to Watch	Completion of the acquisition, results from the ongoing KYRON Phase Ib/IIa study and subsequent FDA discussions on the evidence and registration pathway for ABS-1230.
Primary Source	Jazz Pharmaceuticals acquisition announcement
Relevant Date	10 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com